PCI术前后GLP-1受体激动剂治疗对ST段抬高心肌梗死心肌保护作用被引量：1

A novel potential therapy of GLP-1 receptor agonists for patients with myocardial infarction undergoing PCI

下载PDF

导出

摘要心肌细胞凋亡的激活决定最终的心肌梗死（myocardial infarction，MI）大小、心室重构以及死亡率[1]。过去10年间，基础研究报道了葡萄糖一胰岛素一钾输液具有抗细胞凋亡作用。有些临床试验利用此输液来治疗sT段抬高心肌梗死。但因大部分试验中发现疗效欠佳或无效而在临床上停止使用此疗法[2]。

作者朱恩波赵光贤成宪武

机构地区延边大学附属医院心血管内科

出处《中国心血管病研究》 CAS 2014年第12期1133-1135,共3页 Chinese Journal of Cardiovascular Research

基金 2012-2015年度国家自然科学基金（项目编号：81260068）

关键词胰高血糖素样肽-1 心肌梗死心肌保护作用心肌功能不全 Glucagon-like peptide-1 Myocardial infarction Myocardial protection Myocardial dysfunction

分类号 R542.22 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献20

1Ravassa S, Zudaire A, Dfez J. GLP-1 and cardioprotection: from bench to bedside. Cardiovasc Res, 2012,94 : 316-323.
2van der Horst IC, Zijlstra F, van "t Hof AW, et al. Glucose-in- sulin-potassium infusion inpatients treated with primary angio- plasty for acute myocardial infarction: the glucose-insulin-potas- sium study: a randomized trial. J Am Coil Cardiol,2003,42: 784-791.
3Timmers L, Henriques JP, de Kleijn DP, et al. Exenatide re- duces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coil Cardiol, 2009,53:501-510.
4Hoist JJ. The physiology of glucagon-like peptide 1. Physiol Rev, 2007,87 : 1409-1439.
5Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally trun- cated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab, 1995,80 : 952-957.
6Lonborg J, Kelbaek H, Vejlstrup N, et al. Exenatide reduces fi- nal infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv, 201,5:288-295.
7Lonborg J, Vejlstrup N, Kelbaek H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocar- dial infarction. Eur Heart J, 2012,33 : 1491-1499.
8Read PA, Hoole SP, White PA, et al. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlu- sion in humans. Circ Cardiovasc Interv, 2011,4 : 266-272.
9Matsubara J, Sugiyama S, Sugamura K, et al. A dipeptidyl pep- tidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol,2012,59: 265-276.
10Monji A, Mitsui T, Bando YK, et al. Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes. Am J Physiol Heart Circ Physiol,2013,305:H295-304.

<12 >

二级参考文献22

1中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬髙型心肌梗死诊断和治疗指南.中华心血管病杂志,2010,38:675-687.
2Jolly SS, Yusul S, Caims J, et al. Radial versus femonal accessfor coronary angiography and intervention in patients with acutecoronary syndroms (RIVAL): a randomized, parallel group multi-centre trial. Lancet,2011,377:1409-1420.
3Cicek G, Uyarel H, Ergelen M,et al. Hemoglobin Ale as aprognosic marker in patients undergoing primary angioplasty foracute myocardial infarction. Coronary Artery Disease,2011,22:131-137.
4Hu dY, Pan CY,Yu JM,et al. The relationship between coronaryartery disease and abnormal glucose regulation in China, the Chi-na survey. Eur Heart J, 2006,27 : 2573-2579.
5America Disbetes Association. Diagnosis and classification of di-abetes mellitus. Disbetes Care, 2010,33 : S204-209.
6Gibson CM,Cannon CP,Muphy SA,et al. Relationship of theTIMImyocardial perfusion grades,flow grades frame count,andpercutaneous coronary intervention to long -term outcomes afterthrombolytic administration in acute myocardial infarction. Circu-lation^^, 105:1909-1913.
7Bartnik M,Ryden 1,Ferrari R,et al. The prevalence of abnormalglucose regulation in patients with coronary artery disease acrossEurope. The Heart Survery on diabetes and the heart. Eur HeartJ,2004,25:1880-1890.
8Undas A,Weik I,Stepien E,et al. Hyperglyemia is associatedwith enhanced thrombin formation,platelet,activation,and fibrinclot resistance to lysis in patients with acute coronary syndrome.Diabetes Care,2008,31:1590-1595.
9Britton KA,Aggarwal V,Chen AY,et al. Noassociation betweenhemoglobin Ale and in -hospital mortality in patients with dia-betes and acute myocardial infarction. Am Heart J,2011,161:657-663.
10Geriello A. Acute hyperglycaemia: a new risk factor during my-ocardial infarction. Eur Heart J, 2005,26 : 328-331.